Sanofi’s Kadmon Bolt-On Bolsters Its General Medicine Division
Deal Adds Transplant Pill Rezurock For Chronic Graft-Versus-Host Disease
Sanofi’s $1.9bn cash purchase of Kadmon surprised many analysts, coming as a bolt-on for the French pharma’s general medicines transplant portfolio rather than its specialty care pipeline, but the overall view was that it made sense.
